Kofax and Rabobank Deliver Featured Presentation on Intelligent Automation at “AI Enabled Enterprise” Event
IRPA/AI-Sponsored Conference Addresses Shift to Intelligent Automation at Enterprise Scale, a Pivotal Moment in Digital Workforce Development
IRVINE, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kofax ® , a leading supplier of Intelligent Automation software to automate and digitally transform end-to-end business processes, will deliver featured presentations at “The AI Enabled Enterprise: Harmonizing RPA, Intelligent Automation and Cognitive,” on November 6, 2018 at the ETC Venues, London. This event marks the fifth annual Automation Innovation Conference sponsored by IRPA/AI, the Institute for Robotic Process Automation (IRPA) and Artificial Intelligence (AI).
“Intelligent Automation is the next step for many enterprises, leveraging technologies to solve large and complex problems, and embracing the need for digital workforce management,” said Chris Huff, Chief Strategy Officer of Kofax. “It’s a real turning point in automation, as more services go digital and organizations recognize their virtual workers are an increasingly vital component of their overall success.”
This conference occurs at a pivotal moment, as interest in the development of the digital workforce spreads across the enterprise. Organizations already leveraging RPA are ahead of the curve and eager to scale automation efforts, shifting from rudimentary RPA deployment to more comprehensive Intelligent Automation implementation. These organizations have reaped the benefits of RPA but are exploring what it means to tap into new efficiencies enterprise-wide. Conference attendees will gain insight on the trends and business models driving global growth of automation and the new realm of digital workforce management.
Chris Huff will introduce a presentation by Kofax customer Rabobank titled “Limitless Possibilities: Robotics Has No Boundaries, Do You?” The session runs from 11:35 a.m. to 12:05 p.m. and explores how 100 virtual employees help eliminate manual tasks freeing the bank’s human teams in several operational domains to concentrate on higher value work and ultimately create a higher focus on customer value.
Huff will also speak during a session on Intelligent Automation, or “next-generation RPA,” which encompasses a much broader range of smart technologies including RPA, cognitive document automation (CDA), machine learning (ML), workflow orchestration, advanced analytics and AI to drive significant business value. Titled “Building an Effective RPA Center of Excellence: Enabling the Bot Factory,” this interactive discussion will explore how organizations can construct a scalable model to handle the challenges revealed by their pilot and pre-pilot automation programs. The session will take place from 2:50 p.m. - 3:30 p.m., and Huff will be joined by moderator Gregory North, President, Globe North; Miriam Deasy, Principal Analyst, Ovum; and Tom Castle, Director of Artificial Intelligence, RBS.
Kofax is a leading supplier of software and solutions to automate and digitally transform human and information intensive processes across front and back office operations. These can dramatically improve customer engagement, greatly reduce operating costs, mitigate compliance risk and increase competitiveness, growth and profitability. Its broad range of software and solutions can be deployed in the cloud or on premise, and include robotic process automation, business process management, multichannel capture and other critically important capabilities. These provide a rapid return on investment to over 20,000 Kofax customers in financial services, insurance, government, healthcare, supply chain, business process outsourcing and other markets. Kofax delivers its software and solutions through its direct sales and services organization and more than 650 indirect channel partners in more than 60 countries throughout the Americas, EMEA and Asia Pacific. For more information, visit kofax.com.
© 2018 Kofax, Inc. Kofax is a registered trademark of Kofax Limited.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Bombardier Will Fully Cooperate with the AMF Review16.11.2018 00:06 | Pressemelding
MONTRÉAL, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Bombardier acknowledges the announcement by the Autorité des marchés financiers (AMF) that it is reviewing the operations surrounding the establishment by Bombardier of an Automatic Securities Disposition Plan (ASDP) in August 2018 and various subsequent announcements. The ASDP had been reviewed by the AMF prior to its establishment on August 15, 2018. Bombardier intends to fully cooperate with the AMF in its review. The Company has taken the necessary measures to suspend all sales of securities pursuant to the ASDP until further notice. About Bombardier With over 69,500 employees across four business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montreal, Canada, Bombardier has product
ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research15.11.2018 22:05 | Pressemelding
LYON, France and CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research. The partnership encompasses NYBC becoming a long-term supplier of donor red blood cells (RBC) to ERYTECH, enabling ERYTECH to diversify and broaden its supply of RBC source materials for the production of eryaspase and future product candidates derived from its proprietary ERYCAPS® platform as the company ramps up clinical development. Specifically for the Phase 3 trial in second-line metastatic pancreatic cancer that recently started enrolling patients in Europe, and the Phase 2 trial in first-line triple negative breast cancer (TNBC), which are both expected to begin enrollment in the United States early in 2019. The partnershi
Zageno Deepens Engagement with Scientists and Vendors through Its Meaningful and Unbiased Rating System for Scientific Products — Scientific Score gets Algorithm Update15.11.2018 15:37 | Pressemelding
Call for Contributions: Zageno’s rating system for scientific products — the Scientific Score — adds a crucial dimension to help research scientists purchase the right material for their experiment. Scientists: share your experimental data and professional experience about products; Life Science Vendors: provide additional product-specific resources and data points to make your products reach the right scientist CAMBRIDGE, Mass. USA and BERLIN, Germany, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., the largest and fastest-growing online marketplace for research materials, today issues an open call for scientists and vendors alike to contribute to the continuous improvement of the Scientific Score. Designed as an unbiased indicator to help purchasing scientists navigate the enormous amount of product information, the Scientific Score is the result of proprietary algorithms calculating and weighing different data points across multiple information formats. Among others, factors like rec
Motiv Ring Expands International Footprint and Delivers Industry-First Sizing Process15.11.2018 15:00 | Pressemelding
The wearable ring lands in 20 new countries and eight new stores, and introduces frictionless sizing method SAN FRANCISCO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Motiv Inc., creators of breakthrough wearable technology, today announced an increase of its product availability through new international availability and a new digital sizing set alternative. Motiv Ring’s international expansion will be through its website MyMotiv.com. Featured countries include: North America (Canada), Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, Latvia, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom, Norway and Switzerland), as well as Japan, Taiwan, Turkey, Australia and New Zealand. Good fit is imperative to great functionality. To date, Motiv Ring users select their sizes after receiving a physical sizing kit in the mail. Releasing in Open Beta , Motiv Ring users will now have the additional option of determining their Motiv size via a
SignalFx Delivers Next Generation of Application Performance Monitoring15.11.2018 15:00 | Pressemelding
The first to enable directed troubleshooting for applications and microservices SAN MATEO, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- SignalFx, the leader in real-time cloud monitoring for infrastructure, microservices, and applications, today unveiled SignalFx Microservices APM™, the industry’s first real-time application performance monitoring solution designed to accelerate troubleshooting for DevOps teams through advanced real-time analytics. Powered by NoSample™ distributed tracing architecture, SignalFx Microservices APM observes every single transaction – not just a small random sample – and reports on every anomaly. With the new Outlier Analyzer™, the most challenging issues can now be pinpointed and resolved with a single click. SignalFx Microservices APM is built on top of SignalFx’s advanced streaming analytics platform for metrics which applies unsurpassed data science in real-time to identify the root cause of critical application problems. Integration with advanced automat
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 201815.11.2018 14:30 | Pressemelding
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry diseases WALTHAM, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York. Members of Minerva’s senior management will be joined by an expert key opinion leader. Discussions will feature the following speakers and topics: Gregory P. Strauss, Ph.D., Assistant Professor; Director: Clinical Affective Neuroscience Laboratory; Director: Georgia Psychiatric Risk Evaluation Program; Depa
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom